Annexin Pharmaceuticals
Business Services · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Kammakargatan 48, Stockholm, Stockholm, ...Phone Number
+46 705755037Website
www.annexinpharma.comRevenue
-Stock Symbol
ANNXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Annexin Pharmaceuticals
Annexin Pharmaceuticals is a clinical stage biotechnology company based in Stockholm, Sweden, specializing in the development of its drug candidate ANXV, which targets phosphatidylserine to address a variety of diseases. The company focuses on therapeutic areas including ophthalmology and oncology, with ongoing clinical studies for conditions such as Retinal Vein Occlusion and cancer. Their innovative approach aims to empower the body to fight, repair, and heal, potentially benefiting many patients. Annexin is listed on First North, Stockholm, and is led by a team with extensive experience in pharmaceutical research and development.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Annexin Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Annexin Pharmaceuticals recently announced quarterly report
Annexin Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Annexin Pharmaceuticals
Funding: Get notified immidiatlly once Annexin Pharmaceuticals has new funding data
Check out if Annexin Pharmaceuticals is spiking on competitors!
Check if Annexin Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Annexin Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Annexin Pharmaceuticals launches new products
Recommended Actions
Find VP level buyers at Annexin Pharmaceuticals
Find more new buyers
Company Profile Activity
Activity Insights
Annexin Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Annexin Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Annexin Pharmaceuticals.
Annexin Pharmaceuticals financials insights
Gather financial insights about Annexin Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Debt
$439K
Annexin Pharmaceuticals Tech Stack
A closer look at the technologies used by Annexin Pharmaceuticals
Most Recent Scoops
Funding
Funding
Left Company
Executive Move
New Hire
Executive Move
Left Company
Executive Move
New Hire
Executive Move
Annexin Pharmaceuticals News & Media
First patient treated in the second dose group in Annexin's RVO study
Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now completed treatment in the company's clinical phase 2 study in patients with retinal vein occlusion (RVO) with the investigational drug candidate ANXV. No limiting treatment-related side effects have been reported and the company has received recommendation to proceed with treatment of patients in the next dose group. An expected accelerated recruitment rate means that last patient in isAnnexin resolves a SEK 35.6 million fully guaranteed rights issue, subject to approval of an Extraordinary General Meeting
NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG-KONG, JAPAN, CANADA, SINGAPORE, RUSSIA, SOUTH KOREA, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OR INVITATION TO ACQUIRE OR SUBSCRIBE FOR ANY SECURITIES IN ANNEXIN PHARMACEUTICALS AB IN ANY JURISDICTION. SEE THE SECTION “IMPORTANT INFORMAAnnexin announces success in the company's cancer initiative
Annexin Pharmaceuticals today announces important progress in the company's preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer cells. Within the framework of Annexin's cancer initiative, the company has successfully produced a so-called conjugate where the drug candidate ANXV is chemically bound to a chemotherapy agent and together forms a new composite molecule. In cell systems outside the body, this ANXV cBioStock Investor Meeting: Annexin Pharmaceuticals
Annexin Pharmaceuticals presented at BioStock Investor Meeting, September 20. The event took place in Stockholm, featuring several exciting life science companies presenting their business cases to investors and potential partners. See the presentation via: BioStock Investor Meeting September 2023 | Annexin Pharmaceuticals - YouTube (https://www.youtube.com/watch?v=cQ38Ar8HJ04) See the interview via: BioStock Investor Meeting | Interview with Annexin | September 2023 - YouTube (https://www.youtu
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Annexin Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Annexin Pharmaceuticals is a clinical stage biotechnology company based in Stockholm, Sweden, specializing in the development of its drug candidate ANXV, which targets phosphatidylserine to address a variety of diseases. The company focuses on therapeutic areas including ophthalmology and oncology, with ongoing clinical studies for conditions such... Read More
